title: Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
abstract: Baseline serum samples from 2815 human immunodeficiency virus (HIV)-positive and 963 HIV-negative women enrolled in 2 cohort studies were tested for immunoglobulin G antibodies to human papillomavirus type 16 (HPV-16) capsids. HPV-16 seropositivity was associated with lifetime number of sex partners (P<.001) among both HIV-positive and HIV-negative women. Approximately 50%-60% of HPV-16 DNA-positive women were HPV-16 positive. HPV-16 seropositivity was associated with HIV infection; however, after adjustment for baseline cervical HPV infection and disease, the association disappeared. Thus, the high seroprevalence of HPV-16 among HIV-positive women may be explained by a high prevalence of HPV of all types. Approximately 50% of HIV-positive women had serological evidence of prior HPV-16 infection, but only approximately 5% had an HPV-16 cervical infection at baseline. Despite the higher prevalence of HPV infection in this group, most HIV-positive women are able to control HPV-16 replication at the cervix, and reactivation, if it occurs, is not very common.
authors.affiliation: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. rviscid1@jhem.jhmi.edu
authors.forename: Raphael P
authors.initials: RP
authors.lastname: Viscidi
authors.forename: Linda
authors.initials: L
authors.lastname: Ahdieh-Grant
authors.forename: Barbara
authors.initials: B
authors.lastname: Clayman
authors.forename: Kelly
authors.initials: K
authors.lastname: Fox
authors.forename: Leslie S
authors.initials: LS
authors.lastname: Massad
authors.forename: Susan
authors.initials: S
authors.lastname: Cu-Uvin
authors.forename: Keerti V
authors.initials: KV
authors.lastname: Shah
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Anastos
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Squires
authors.forename: Ann
authors.initials: A
authors.lastname: Duerr
authors.forename: Denise J
authors.initials: DJ
authors.lastname: Jamieson
authors.forename: Robert D
authors.initials: RD
authors.lastname: Burk
authors.forename: Robert S
authors.initials: RS
authors.lastname: Klein
authors.forename: Howard
authors.initials: H
authors.lastname: Minkoff
authors.forename: Joel
authors.initials: J
authors.lastname: Palefsky
authors.forename: Howard
authors.initials: H
authors.lastname: Strickler
authors.forename: Paula
authors.initials: P
authors.lastname: Schuman
authors.forename: Eva
authors.initials: E
authors.lastname: Piessens
authors.forename: Paolo
authors.initials: P
authors.lastname: Miotti
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology / Q000821:virology; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D016015:Logistic Models; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications* / Q000175:diagnosis / Q000276:immunology* / Q000821:virology; D012307:Risk Factors; D014412:Tumor Virus Infections / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000821:virology; D014626:Vaginal Smears; D014775:Virus Activation
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G